Table 5.
Regularly used anti-osteoporotic drugs for osteoporosis management.
| Drugs | Generic drugs | Men (dosage) | Women (dosage) |
|---|---|---|---|
| Bisphosphonates | |||
| Alendronate | Fosamax, Fosamax Plus D, Binosto | 5 mg; 10 mg daily | 5 mg; 10 mg daily |
| Ibandronate | Boniva | 3 mg IV every 3 months | 2.5 mg daily; 150 mg once monthly |
| Risedronate | Actonel, Atelvia | 5 mg daily or 35 mg once weekly | 5 mg daily or 35 mg once weekly |
| Zoledronic acid | Reclast | 5 mg IV once yearly | 5 mg IV once yearly |
| RANKL Inhibitor | |||
| Denosumab | Prolia | 60 mg/mL | 60 mg/mL |
| Estrogen Agonist/Antagonists | |||
| Raloxifene | Evista | – | 60 mg/day |
| Conjugated estrogens/bazedoxifene | Duavee (Pfizer) | – | 0.45–20 mg/day |
| Parathyroid Hormone Analogues | |||
| Recombinant human PTH 1-34 | Teriparatide (Forteo); Abaloparatide (Tymlos) | 20 μg/day IV for 2 years | 20 μg/day IV for 2 years |
| Recombinant human PTH 1-84 | 100 μg/day IV for 2 years | 100 μg/day IV for 2 years | |
| Calcitonin-Salmon | Generic | 200 IU/mL | 1 spray daily |
| Miacalcin (Novartis) | 200 IU/mL | 100 IU daily | |
Where; μg/day: Microgram/day; IU/mL: International Units Per Milliliter; IV: Intravenous; mg/ml:milligrams per milliliter.